Original Publication Date: 14 February, 2014
Publication / Source: Breast Cancer Management
Authors: Peter Gilbar, Ian McPherson, Natacha Sorour, Jasotha Sanmugarajah, Alessandra Francesconi & Elizabeth McCaffrey
Lakhanpal et al. conducted a multicenter retrospective audit in seven Australian centers to determine the incidence of febrile neutropenia (FN) and neutropenia associated with the use of docetaxel plus cyclophosphamide (TC) in women with early breast cancer who did not receive primary prophylaxis with G-CSF or antibiotics . Of the 300 evaluable female patients 73 (24.3%) developed FN with the incidence higher after cycle 1 of TC.